C12N 2830/48
Regulating transport or export of rna
Official title: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
C12N2830/48 (Regulating transport or export of rna) appears on 250 US grants and 623 published applications in this corpus.
Search patents in C12N- Granted patents
- 250
- Published applications
- 623
- Assignees
- 322
- Inventors
- 1,247
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 1 |
| 2002 | 7 | 6 |
| 2003 | 3 | 26 |
| 2004 | 2 | 16 |
| 2005 | 5 | 24 |
| 2006 | 8 | 13 |
| 2007 | 10 | 12 |
| 2008 | 6 | 17 |
| 2009 | 6 | 8 |
| 2010 | 11 | 9 |
| 2011 | 7 | 12 |
| 2012 | 6 | 3 |
| 2013 | 8 | 10 |
| 2014 | 6 | 6 |
| 2015 | 9 | 15 |
| 2016 | 8 | 9 |
| 2017 | 11 | 20 |
| 2018 | 8 | 14 |
| 2019 | 13 | 17 |
| 2020 | 13 | 29 |
| 2021 | 9 | 30 |
| 2022 | 15 | 65 |
| 2023 | 15 | 53 |
| 2024 | 24 | 74 |
| 2025 | 17 | 87 |
| 2026 | 18 | 47 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating Dravet syndrome29 Sep 2026US 12,747,452 B2New York University
- Lentiviral vectors in hematopoietic stem cells to treat Wiskott-Aldrich syndrome (WAS)25 Aug 2026US 12,714,732 B2The Regents of the University of California
- Genomic insulator element exhibiting enhancer blocking activities in lymphocytes and uses thereof11 Aug 2026US 12,702,720 B2St. Jude Children?S Research Hospital
- DNA origami encoding for gene expression and contransfection4 Aug 2026US 12,698,510 B2Technische Universität München
- AAV delivery of nucleobase editors30 Jun 2026US 12,668,815 B2President and Fellows of Harvard College
- Retroviral vectors8 Oct 2026US 2026/0308619 A1UCL Business PLC
- Compositions comprising smyd1 and methods of use thereof8 Oct 2026US 2026/0308621 A1
- Epigenetic targets for enhancing cancer immunotherapy1 Oct 2026US 2026/0295086 A1Duke University
- Cell therapies for type 1 diabetes24 Sep 2026US 2026/0285937 A1Abata Therapeutics, Inc.
- Guide nucleic acids targeting vegfa and uses thereof24 Sep 2026US 2026/0286348 A1Huidagene Therapeutics (Singapore) Pte. Ltd.
Most cited
By later US patents
- Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor346US 7,906,111 B2The Trustees of the University of Pennsylvania · 2011
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor220US 7,790,449 B2The Trustees of the University of Pennsylvania · 2010
- Method for detecting adeno-associated virus165US 8,524,446 B2The Trustees of the University of Pennsylvania · 2013
- Vectors and methods for the efficient generation of integration/transgene-free induced pluripotent stem cells from peripheral blood cells126US 9,850,499 B2Loma Linda University · 2017